KLK3 and xerostomia: Two patients in highly challenging clinical situations showed a positive response to 225Ac-PSMA-617 therapy–both experienced a complete response with prostate-specific antigen decline and no hematologic toxicity, with manageable xerostomia as the only notable side effect (85).